Difficulty: Medium
Average Score: 89%
Practice
A client has a new prescription for Adalimumab for Rheumatoid Arthritis. Based on the route of administration of Adalimumab, which of the following should the nurse plan to monitor?
Correct answer
B
Rationale
In this scenario, the correct answer is B) The subcutaneous site for redness following injection. Adalimumab is typically administered subcutaneously for the treatment of Rheumatoid Arthritis. Monitoring the injection site for redness is essential as it can indicate a local reaction or infection. This monitoring helps in early detection of any adverse effects and allows for prompt intervention if needed.
Option A) monitoring the vein for thrombophlebitis during IV administration is incorrect because Adalimumab is not administered intravenously, making this monitoring unnecessary and irrelevant to this medication.
Option C) monitoring the oral mucosa for ulceration after oral administration is also incorrect as Adalimumab is not administered orally. It is essential to match the appropriate route of administration with the monitoring parameters.
Option D) monitoring the skin for irritation following removal of a transdermal patch is also incorrect since Adalimumab is not administered via transdermal patches. Understanding the correct route of administration for each medication is crucial in determining the appropriate monitoring parameters.
Educationally, this question highlights the importance of understanding the routes of administration of medications and the corresponding monitoring requirements. Nurses need to be knowledgeable about the specific characteristics of each medication to provide safe and effective care to their patients. Monitoring for adverse effects is a crucial aspect of pharmacological management, and this question reinforces the significance of vigilance in assessing patients for potential complications related to medication administration.
Option A) monitoring the vein for thrombophlebitis during IV administration is incorrect because Adalimumab is not administered intravenously, making this monitoring unnecessary and irrelevant to this medication.
Option C) monitoring the oral mucosa for ulceration after oral administration is also incorrect as Adalimumab is not administered orally. It is essential to match the appropriate route of administration with the monitoring parameters.
Option D) monitoring the skin for irritation following removal of a transdermal patch is also incorrect since Adalimumab is not administered via transdermal patches. Understanding the correct route of administration for each medication is crucial in determining the appropriate monitoring parameters.
Educationally, this question highlights the importance of understanding the routes of administration of medications and the corresponding monitoring requirements. Nurses need to be knowledgeable about the specific characteristics of each medication to provide safe and effective care to their patients. Monitoring for adverse effects is a crucial aspect of pharmacological management, and this question reinforces the significance of vigilance in assessing patients for potential complications related to medication administration.